- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06068855
성인 참가자의 교근 돌출부 변화에 대한 BOTOX(보툴리눔 독소 A형) 주사의 효과를 평가하기 위한 연구 (MMP EU P3)
교근 돌출부 감소를 위한 BOTOX®(보툴리눔 독소 A형): 제3상, 다기관, 무작위 배정, 이중 맹검, 위약 대조 연구
The masseter muscle is one of the muscles in the lower face used for chewing. Prominence of the masseter muscle can appear as a widened and square lower face shape, which is an aesthetic concern for individuals who prefer a narrower and more ovoid lower face shape. Treatments are available for masseter muscle prominice (MMP), but researchers are looking for new non-surgical treatments. This study will assess adverse events and effectiveness of BOTOX in adult participants with MMP.
BOTOX is being investigated for the treatment of MMP. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is 1 in 4 chance that participants will be assigned to placebo. Around 248 adult participants with MMP will be enrolled in the study at approximately 30 sites in Europe.
Participants will receive either BOTOX or Placebo administered as 6 intramuscular injections to the masseter on Day 1. Participants who are eligible for retreatment will be given BOTOX on Day 180 and will be followed for up to 6 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
연구 개요
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Hamburg, 독일, 20146
- Universitaet Hamburg /ID# 247503
-
-
Bavaria
-
Munich, Bavaria, 독일, 80333
- Hautok and Hautok-cosmetics /ID# 246600
-
Munich, Bavaria, 독일, 80333
- Studienzentrum Theatiner46 /ID# 246601
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, 독일, 50996
- Hautzentrum Koeln /ID# 247502
-
Düsseldorf, North Rhine-Westphalia, 독일, 40212
- Privatpraxis Dr. Hilton & Partner /ID# 246602
-
-
-
-
Antwerpen
-
Beerse, Antwerpen, 벨기에, 2340
- Da Vinci Clinic /ID# 246731
-
Schilde, Antwerpen, 벨기에, 2970
- Evolve Clinic /ID# 246729
-
-
Brussels Capital
-
Jette, Brussels Capital, 벨기에, 1090
- Universitair Ziekenhuis Brussel /ID# 246311
-
-
Oost-Vlaanderen
-
Melle, Oost-Vlaanderen, 벨기에, 9090
- Lightfalls Clinic /ID# 247335
-
-
-
-
-
Plovdiv, 불가리아, 4000
- Dermavist - Group Practice for Specialized Medical Care for Skin Disease /ID# 247630
-
Sofia, 불가리아, 1700
- Medical Centre Dermatology Dr. Denkova EOOD /ID# 246591
-
Sofia, 불가리아, 1407
- Medical Center Derma Vita EOOD /ID# 247327
-
-
-
-
-
Madrid, 스페인, 28006
- Grupo Pedro Jaen /ID# 246485
-
Madrid, 스페인, 28008
- Clinica Robega /ID# 252239
-
-
Pontevedra
-
Vigo, Pontevedra, 스페인, 36201
- Gavín Dermatólogos /ID# 252120
-
-
Valencia
-
Valencia, Valencia, 스페인, 46004
- Clinica Alejandria /ID# 247380
-
-
-
-
-
Edinburgh, 영국, EH3 6RS
- Dr Nestor's Medical Cosmetic Centre /ID# 246437
-
London, 영국, W1H 6AZ
- Interface Aesthetics Training Limited /ID# 248115
-
Sutton Coldfield, 영국, B74 2UG
- MediZen /ID# 246431
-
-
North Lanarkshire
-
Coatbridge, North Lanarkshire, 영국, ML5 3AP
- Waverley Medical Practice /ID# 246432
-
-
-
-
-
Latina, 이탈리아, 04100
- Azienda Unita Sanitaria Locale Latina /ID# 246835
-
Roma, 이탈리아, 00128
- Fondazione Policlinico Universitario Campus Bio-Medico /ID# 246836
-
Verona, 이탈리아, 37134
- CRC - Centro Ricerche Cliniche di Verona S.r.l. /ID# 246834
-
-
-
-
-
Antibes, 프랑스, 06160
- Mediti /Id# 246875
-
Cannes, 프랑스, 06400
- Cabinet Dermatologie et Esthetique /ID# 246871
-
Paris, 프랑스, 75007
- Cabinet médical /ID# 246873
-
Toulouse, 프랑스, 31000
- Cabinet de Chirurgie Plastique et Esthétique /ID# 246872
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Body mass index < 30 kg/m^2 using the calculation: BMI = weight (kg)/height (m)^2, rounded to the nearest whole number.
-
Participants meets the following criteria:
- Bilateral Grade 4 or Grade 5 MMP (identical grades for left and right side of the face), as determined at screening and at the Day 1 visit by the investigator using the MMPS.
- Bilateral Grade 4 or Grade 5 MMP (identical grades for left and right sides of the face), as determined at the Day 1 visit by the participant using the MMPS-P.
- MMP grades, as assessed by investigator and participant, do not need to be identical but have to be a minimum of Grade 4 with bilateral symmetry at Day 1.
-
Participants who responded "A lot" or "Extremely" bothered by the appearance of their MMP as measured by the Bother Impact Assessment for Masseter Muscle Prominence (BIA-MMP) and attain a total score of ≥ 15 on the Lower Facial Shape Questionnaire - Impact Assessment (LFSQ-IA), determined at the Day 1 visit.
Exclusion Criteria:
- Has current intraoral infection, including infection of the mouth or gums, or facial skin infection requiring medical treatment in the opinion of the investigator.
- Has weakness of the masseter, pterygoid, or temporalis muscles due to trauma, facial nerve injury, or other condition that could interfere with normal chewing and jaw clenching, as determined by the investigator.
- Excess lower facial fat, jowling, loose or lax skin in lower face, or parotid gland prominence that could interfere with MMPS or MMPS-P grading, as determined by the investigator.
- Has medical condition that may put the participant at increased medical risk with exposure to BOTOX, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function.
- History of dental or surgical procedure for lower facial shaping or masseter muscle reduction.
- History of any soft tissue fillers in the jawline.
- Has prior exposure to botulinum toxin of any serotype to any part of the body (not including masseter muscle) within the 3 months prior to Day 1.
- History of or current TMJD, or presence of signs/symptoms of possible TMJD in the opinion of the investigator.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 순차적 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Double-Blind Period: Botox
Participants will receive 6 intramuscular injections of BOTOX to the masseter on Day 1. |
Intramuscular Injections
다른 이름들:
|
|
실험적: Open-Label Period: Botox
Participants who are eligible for retreatment will be given open-label BOTOX on Day 180 and will be followed for up to 6 months |
Intramuscular Injections
다른 이름들:
|
|
위약 비교기: Double Blind Period: Placebo
Participants will receive 6 intramuscular injections of Placebo to the masseter on Day 1. |
Intramuscular Injections |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Achievement of 2-grade or more improvement from baseline on the Masseter Muscle Prominence Scale (MMPS) as assessed by the Investigator
기간: Day 90
|
The investigator assessed the severity of the participant's MMP using the MMPS 5-point scale where: 1=minimal (best), 2=mild, 3=moderate, 4=marked, and 5=very marked (worst). |
Day 90
|
|
Achievement of 2-grade or more improvement from baseline on the Masseter Muscle Prominence Scale - Participant (MMPS-P) as assessed by the Participant
기간: Day 90
|
The participant assessed the severity of their MMP using the MMPS-P 5-point scale where: 1=not at all pronounced (best), 2=mildly pronounced, 3=moderately pronounced, 4=pronounced, and 5=very pronounced (worst). |
Day 90
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Response of "Very Satisfied" or "Satisfied" on the Lower Facial Shape Questionnaire - Treatment Satisfaction Assessment (LFSQ-TXSAT)
기간: Day 90 to Day 180
|
The LFSQ-TXSAT measures the participant's satisfaction with the effect of treatment on the appearance of their lower face where 2=Very satisfied, 1=Satisfied, 0=Neither satisfied nor dissatisfied, -1=Dissatisfied, -2=Very dissatisfied. |
Day 90 to Day 180
|
|
Response of "Not at all bothered" or "A little bothered" on the Bother Impact Assessment for Masseter Muscle Prominence (BIA-MMP)
기간: Day 90 to Day 180
|
The BIA-MMP is a single item evaluation of how bothered the participant is by the appearance of their lower face where 0=Not at all bothered, 1=A little bothered, 2=Somewhat bothered, 3=A lot bothered, 4=Extremely bothered. |
Day 90 to Day 180
|
|
Change from baseline in lower facial volume (cm^3)
기간: Day 90
|
Lower facial volume is calculated from standardized images |
Day 90
|
|
Change from baseline in lower facial width (mm)
기간: Day 90
|
Lower facial width is calculated from standardized images |
Day 90
|
|
Change from baseline in Lower Facial Shape Questionnaire - Impact Assessment (LFSQ-IA) summary score
기간: Day 90 to Day 180
|
The LFSQ-IA is a 6-item assessment that measures psychosocial impact of the appearance of the lower face where 0= Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit and 4=Extremely. |
Day 90 to Day 180
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: ABBVIE INC., AbbVie
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- M23-123
- 2022-500568-37-00 (기타 식별자: EU CT)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD 공유 기간
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD 공유 액세스 기준
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .